Immunohistochemical Expression of Vitamin D Receptor (VDR) in Urinary Bladder Squamous Cell Carcinoma
- PMID: 38265102
- PMCID: PMC11131569
- DOI: 10.5146/tjpath.2023.12863
Immunohistochemical Expression of Vitamin D Receptor (VDR) in Urinary Bladder Squamous Cell Carcinoma
Abstract
Objective: Squamous cell carcinoma (SCC) of the urinary bladder is associated with aggressive behavior and is typically treated with radical cystectomy. Vitamin D receptor (VDR) and its ligand Calcitriol have shown anti-tumor effects in various malignancies but to our knowledge there is no current information on VDR expression in bladder SCC. This study aimed to assess VDR immunostaining patterns in pure bladder SCC and its relation to the available clinicopathological parameters of such tumors.
Material and methods: VDR immunostaining was performed on 35 radical cystectomy specimens from patients with primary pure SCC. Nuclear and cytoplasmic VDR staining was scored separately using the semi-quantitative immunoreactive score.
Results: Nuclear and cytoplasmic/membranous VDR expression was present in 35 (100%) and 19 (54.3%) cases, respectively, with a significant negative linear relationship (r=-0.33; p=0.035). Differences in cytoplasmic/membranous VDR expression were found in relation to tumor histology (p=0.018), tumor necrosis (p=0.022), and stage groups (p=0.001). Low cytoplasmic VDR correlated with increased tumor staging (Cc = -0.422), positive lymph node status (Cc = -0.375), and higher stage groups (Cc= -0.438). The median nuclear VDR expression score was significantly higher in advanced stage groups (p= 0.038).
Conclusion: Our data suggest that VDR may be a potential prognostic factor in bladder SCC. Further studies and clinical trials using vitamin D supplements may provide a new therapeutic option for those high-risk patients.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.Urol Oncol. 2019 Jul;37(7):478-484. doi: 10.1016/j.urolonc.2019.02.017. Epub 2019 Mar 23. Urol Oncol. 2019. PMID: 30910351
-
Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival of Urothelial Bladder Cancer Patients.Int J Mol Sci. 2015 Oct 15;16(10):24369-86. doi: 10.3390/ijms161024369. Int J Mol Sci. 2015. PMID: 26501255 Free PMC article.
-
Oncologic Outcomes of Squamous Cell Carcinoma Versus Urothelial Carcinoma With Squamous Differentiation After Radical Cystectomy for Bladder Carcinoma.Clin Genitourin Cancer. 2022 Apr;20(2):148-154. doi: 10.1016/j.clgc.2021.12.011. Epub 2021 Dec 16. Clin Genitourin Cancer. 2022. PMID: 34998698
-
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies.Urol Int. 2024;108(1):1-8. doi: 10.1159/000534858. Epub 2023 Dec 21. Urol Int. 2024. PMID: 38128507 Free PMC article. Review.
-
Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches.Arab J Urol. 2016 Aug 1;14(3):183-91. doi: 10.1016/j.aju.2016.07.001. eCollection 2016 Sep. Arab J Urol. 2016. PMID: 27547458 Free PMC article. Review.
References
-
- Sung Hyuna, Ferlay Jacques, Siegel Rebecca L., Laversanne Mathieu, Soerjomataram Isabelle, Jemal Ahmedin, Bray Freddie. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. May;2021 CA Cancer J Clin. 71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
-
- Martin Jeremy W., Carballido Estrella M., Ahmed Ahmed, Farhan Bilal, Dutta Rahul, Smith Cody, Youssef Ramy F. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Sep;2016 Arab J Urol. 14:183–191. doi: 10.1016/j.aju.2016.07.001. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials